Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report

• Margaret Corrigan,
• Geoffrey Haydon,
• Fiona Thompson,
• Neil Rajoriya,
• Claire L Peplow,
• Stefan G Hubscher,
• Neil Steven,
• Gideon M Hirschfield,
• Matthew J Armstrong

Affiliations

Margaret Corrigan

National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, UK; The Liver Unit, Queen Elizabeth University Hospitals Birmingham, Birmingham, UK; Corresponding authors. Address: Liver Unit, 3rd floor Nuffield House, Queen Elizabeth University Hospital Birmingham, Birmingham, UK.

Geoffrey Haydon

The Liver Unit, Queen Elizabeth University Hospitals Birmingham, Birmingham, UK

Fiona Thompson

The Liver Unit, Queen Elizabeth University Hospitals Birmingham, Birmingham, UK

Neil Rajoriya

The Liver Unit, Queen Elizabeth University Hospitals Birmingham, Birmingham, UK

Claire L Peplow

The Liver Unit, Queen Elizabeth University Hospitals Birmingham, Birmingham, UK

Stefan G Hubscher

Department of Cellular Pathology, University Hospitals Birmingham, Birmingham, UK

Neil Steven

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK

Gideon M Hirschfield

National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, UK; The Liver Unit, Queen Elizabeth University Hospitals Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Canada

Matthew J Armstrong

National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, UK; The Liver Unit, Queen Elizabeth University Hospitals Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Corresponding authors. Address: Liver Unit, 3rd floor Nuffield House, Queen Elizabeth University Hospital Birmingham, Birmingham, UK.